Revenue Breakdown
Composition ()
No data
Revenue Streams
Pfizer Inc (PFE) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Eliquis alliance revenues and direct sales, accounting for 12.1% of total sales, equivalent to $2.02B. Other significant revenue streams include Prevnar family and Vyndaqel family. Understanding this composition is critical for investors evaluating how PFE navigates market cycles within the Pharmaceuticals industry.
Profitability & Margins
Evaluating the bottom line, Pfizer Inc maintains a gross margin of 64.15%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 26.81%, while the net margin is -9.34%. These profitability ratios, combined with a Return on Equity (ROE) of 8.87%, provide a clear picture of how effectively PFE converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, PFE competes directly with industry leaders such as BMY and VRTX. With a market capitalization of $155.01B, it holds a leading position in the sector. When comparing efficiency, PFE's gross margin of 64.15% stands against BMY's 65.34% and VRTX's 85.39%. Such benchmarking helps identify whether Pfizer Inc is trading at a premium or discount relative to its financial performance.
